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BIOFILM-INHIBITING EFFECT AND 
ANTI-INFECTIVE ACTIVITY OF N,C 
LINKED ARYLISOQUINOLINES AND THE 
USE THEREOF 
[0001] The present invention relates to the anti-infective 
(anti-candida, anti-leishmania, antitrypanosoma, anti-plas 
modium) as Well as bio?lm-inhibiting activities of N,C 
bonded aryl isoquinoline-derivatives and their uses, in par 
ticular as bioactive drugs for biotechnological and medical 
uses, especially for the prevention of the formation of bio 
?lms by human pathogenic bacteria, and the anti-infective 
potential of speci?c members of said compounds against the 
pathogens plasmodia, trypanosoma, and leishmania. 
BACKGROUND OF THE INVENTION 
[0002] According to the report on World health 2002 of the 
World Health Organization (WHO), World-Wide infectious 
diseases still are the main cause of death. In particular in the 
developing countries each year millions of people die from 
the implications of malaria, sleeping sickness, Chagas-dis 
ease, leishmaniosis, candida-infections and other infectious 
diseases. Whereas in the industrialized countries the classical 
infectious diseases initially appeared to be defeated (2002: 
7% of the fatal cases in Germany), these are progressing 
World-Wide again: Many of the common drugs loose their 
effect because of the increasing resistance of the pathogens. 
These also include Gram-positive bacteria, such as staphylo 
cocci and enterococci that can cause septicemia and other 
infections, mainly in immune-suppressed patients. The 
methicillin and oxacillin-resistant staphylococci (MRSA, 
ORSA), the vancomycin-resistant enterococci, and the multi 
resistant pseudomonades are to be mentioned as particularly 
problematic germs. 
[0003] In addition to the increasing generation of resistance 
of microbial pathogens, their formation of bio?lms is a large 
problem. Bio?lms are understood as a community of micro 
organisms that is coated With an extracellular polysaccharide 
or protein-matrix, Whereby the individual cells are able to 
stick to another and/or to surfaces (J. W. Costerton, Z. LeWan 
doWski, D. E. CaldWell, D. R. Korber, H. M. Lappin-Scott, 
Annu. Rev. Microbiol. 1995, 49, 711-745; P. Stoodley, K. 
Sauer, D. G. Davies, J. W. Costerton, Annu. Rev. Microbiol. 
2002, 56, 187-209). 
[0004] Thereby, the microbial community can be com 
posed of one or even several species. The organiZation of cells 
in a bio?lm leads to a markedly increased resistance of the 
overall population against a large variety of in?uences. Thus, 
bio?lms are not to be understood as a group of individual 
cells. Rather, they are similar in their physiology to a multi 
cellular organism, in Which a different gene expression and 
metabolic activity, dynamics, and division of labor is found. 
[0005] Bio?lms are Widely found in nature. They can be 
preferably found at the interfaces betWeen the solid and liquid 
phase, and possibly are the primary life-form of microorgan 
isms in the aquatic milieu (rivers, lakes, oceans, etc.). They 
also cause an essential economic damage in shipping through 
the formation of bio?lms on those parts of ships that are 
located under Water. Then, these are the organic matrix for the 
further groWth of mussels or bryoZoans. This secondary 
groWth on of the hull of ships can reach a thickness of several 
decimeters, and leads to a drastic increase of the drag of Water 
and thus to a reduction of the maneuverability and the speed 
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of the ships, and to an increased consumption of fuel. Never 
theless, bio?lms can also become a threat for humans. Indeed, 
bio?lm-forming human pathogenic bacteria represent an 
important cause for chronic and recurring infections in 
human medicine. Prominent examples for this are the forrna 
tion of plaque on teeth by streptococci, the formation of 
alginate of Pseudomonas aeruginosa in lung infections in the 
context of a cystic ?brosis, and, last but not least, the coloni 
Zation of plastic and metal implants by bio?lm-forming sta 
phylococci in modern intensive care medicine. 
[0006] In vieW of the increasing importance of nosocomial 
infections, We have concentrated our attempts on the identi 
?cation of bio?lm-inhibiting drugs against multi-resistant 
Staphylococcus-aureus and S.-epidermidis-pathogens. These 
bacteria mainly occur in connection With the use of plastic 
and metal implants. In particular in immune-suppressed 
patients they can cause severe general infections that are 
mainly caused by Staphylococcus epidermidis and Staphylo 
coccus aureus. Both species form bio?lms on arti?cial sur 
faces (eg on venous catheters, pacemakers or on joint 
replacements) that consist of the bacteria themselves and a 
polysaccharide matrix. This matrix, Which is also designated 
as Polysaccharide-Intercellular-Adhesin (PIA), consists of 
[3-1,6-bonded glucosaminoglycane-subunits that are substi 
tuted With different side groups (D. Mack, W. Fischer, A. 
Krokotsch, K. Leopold, R. Hartmann, H. Egge, R. Lauts, J. 
Bacteriol. 1996, 178, 175-183). The substance mediates the 
adherence of the cells With another, and thus is responsible for 
the three-dimensional, multi-layered groWth of a staphylo 
coccal bio?lm. Until today, four proteins, IcaA, IcaD, IcaB, 
and IcaC, could be identi?ed that are involved in PIA-synthe 
sis (C. Hellmann, O. SchWeitZer, C. Gerke, N. Vanittanakom, 
D. Mack, F. GotZ, Mol. Microbial. 1996, 20, 1083-1091; C. 
Gerke, A. Kraft, R. Siissmuth, O. SchWeitZer, F. GotZ, J. Biol. 
Chem. 1998, 29, 18586-18593). The genes that encodes for 
these enZymes are organiZed in the so-called icaADBC-op 
eron, Which so far Was identi?ed in all S.-aureus-isolates as 
tested, and in 70 to 80 percent of all S.-epidermidis-strains 
from foreign matter-associated infections (W. Ziebuhr, C. 
Heilmann, F. GotZ, P. Meyer, K. Wilms, E. Straube, J. Hacker, 
Infect. Immun. 1997, 65, 890-896; S. E. Cramton, C. Gerke, 
N. F. Schnell, W. W. Nichols, F. GotZ, Infect. Immun. 1999, 
67, 5427-5433). 
[0007] Although the PIA, according to all ?ndings so far, is 
the most important factor for the generation of a bio?lm in 
staphylococci, nevertheless, also additional components are 
involved in this. It Was shoWn that the establishment of a 
bio?lm takes place in tWo phases. The ?rst phase ?rst requires 
the adherence of the staphylococci on the surface, in the 
second phase folloWed by the PIA-mediated accumulation of 
the bio?lm. The ?rst phase of the formation of the bio?lm, 
Which is also designated as initial adherence, is mediated in S. 
epidermidis by a surface protein, Which is knoWn as AtlE (C. 
Heilmann, M. Hussain, G. Peters, F. GotZ, Mol. Microbial. 
1997, 24, 1013-1024). In addition to the initial adherence, 
AtlE also has another function in the cell of the staphylococ 
cus. It is involved as autolysin-protein in the separation of the 
cell Wall during cellular division. Mutations in the atlE-gene 
thus lead to an inhibition of the formation of bio?lms on 
surfaces and to a generation of cellular aggregates in the 
supernatant of the culture (C. Heilmann, M. Hussain, G. 
Peters, F. GotZ, Mol. Microbial. 1997,24, 1013-1024). Most 
recently, additional factors Were detected that are involved in 
the formation of bio?lms of staphylococci. Members of these 
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are teichoic acids that make up for an essential part of the 
bio?lm-matrix (l. Sadovskaya, E. Vinogradov, S. Flahaut, G. 
Kogan, S. Jabbouri, Infect Immun 2005, 73, 3007-3017.) 
Similarly, tWo surface-associated proteins, Aap and Bap, 
Were identi?ed that can mediate the accumulative phase of the 
formation of bio?lms independently of ica and PIA (H. 
Rohde, C. Burdelski, K. Bartscht et al., Mal. Microbial. 2005, 
55, 1883-1895; C. Cucarella, C. Solano, J.Valle, B.Amorena, 
1. Lasa, J. R. Penades, J. Bacterial. 2001, 183, 2888-2896.) 
[0008] Furthermore, for some of the compounds an out 
standing activity against trypanosomes couldbe found. These 
single-cell parasites are important pathogens in the veteri 
nary, but especially in human, medicine. According to infor 
mation provided by the World Health Organization, every 
year 300.000 to 500.000 humans suffer from sleeping sick 
ness that is caused by lrypanosoma brucei (A. Stich, P. M. 
Abel, S. Krishna, BMJ. 2002, 325, 203-206). Without 
therapy, the disease ends fatally. The medicaments as cur 
rently available have a lot of side effects, can not be obtained 
everyWhere, and often are not effective enough. Therefore, 
neW medical options are urgently needed (A. Stich, M. P. 
Barrett, S. Krishna Trends Parasil. 2003, 19, 195-197). 
[0009] It is therefore an object of the present invention to 
provide novel, highly effective and non-toxic substances, 
Which, in particular, can be used for an improved inhibition of 
the formation of bio?lms, as Well as for a treatment of dis 
eases, such as, for example, infectious diseases. 
[0010] This object is solved by the N,C-bonded aryl iso 
quinolines of the general formulae 1 to 3, 
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wherein R1 to R6 and R8 to R12 independently are either H, a 
non-substituted, monosubstituted or polysubstituted C l-C 18 
alkyl, Wherein the alkyl can be straight, branched or cyclic, 
alkenyl, a non-substituted, monosubstituted or polysubsti 
tuted aryl or heteroaryl residue, a non-substituted, monosub 
stituted or polysubstituted benZyl group, an acyl group, such 
as, for example, formyl, acetyl, trichloroacetyl, fumaryl, 
maleyl, succinyl, benZoyl, or a branched or heteroatom- or 
aryl-sub stituted acyl group, an alkoxy sub stituent, such as, for 
example, 4OMe, 4OEt, 4OnPr, -iPr, 4OnBu, iOiBu, 
4OsecBu, 4OtBu, the alkyl group thereof is branched, non 
branched or cyclic, an alkyl group bound through a sulfur 
atom, such as, for example, iSMe, iSEt, or a sulfonyl 
group, such as, for example, iSO3H, iSOzMe, iSO2CF3, 
iSO2C6H4CH3 or SO2C6H4CH2Br, or a nitrogen substitu 
ent, such as, for example, iNHZ, iNHR, iNRR' (With R, 
R'Ialkyl, aryl etc.), iNC or iNOZ, or ?uoro, chloro, bromo, 
iodo, iCN or a hetero substituent, 
[0011] R7 independently can be either H, a non-substituted, 
monosubstituted or polysubstituted Cl-Cls-Alkyl, Wherein 
the alkyl can be straight, branched or cyclic, a monosubsti 
tuted or polysubstituted, straight, branched or cyclic C l-C l8 
alkenyl or can be an acyl group, such as, for example, formyl, 
acetyl, trichloroacetyl, fumaryl, maleyl, succinyl, benZoyl, 
branched or heteroatom- or aryl-substituted acyl groups, 
[0012] and R8 to R12 can also be bonded in a manner that 
thereby a non-substituted, monosubstituted or polysubsti 
tuted ring and dimers of 1 is generated, as Well as pharma 
ceutically acceptable salts or solvates, With the provisio that 
the folloWing substances are excluded from the above-men 
tioned compounds according to the invention: 
MeO Me \ 
(9 
/ N 
MeO Me 
OMe 
Me OMe 
MeO \\\Me 
/ N® 
MeO Me 
OMe 
Me OMe 
MeO \\\ 
S\“ OH OMe 
(9 
/ N 
MeO Me 
Me 
MeO Me \ 
(*3 
/ N 
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-continued 
MeO Me 
MeO Me 
[0013] In vieW of the increasing importance of hospital 
derived infections, the inventors have concentrated their 
efforts on the identi?cation of novel drugs against multi 
resistant Slaphylococcus-aureus and S.-epidermidis patho 
gens, since these are responsible for the largest number of 
ho spital-derived infections. Thereby, not only the approach of 
searching for those that are effective in the bacteriostatic or 
bactericidal killing of the pathogens, but particularly those 
compounds are sought for that interfere With the gene regu 
lation and gene expression of virulence factors. This concept 
appears to be reasonable in particular With foreign matter 
associated staphylococcal infections. Staphylococci form 
bio?lms on plastic and metal surfaces of medical implants, 
thus representing a major source for persisting and recurring 
infections. A prevention of the formation of bio?lms or their 
dissolution and removal Would markedly contribute to a 
therapy of nosocomial infections. 
[0014] A further aspect of the present invention relates to 
the use of a series of the above-mentioned compounds for a 
treatment of infectious diseases, such as leishmaniosis and 
trypanosomal diseases (such as the African sleeping sickness 
or Chagas-disease). Indeed, it could be found that, upon a 
modi?cation of the different structural parameters, conve 
niently the selectivity of the activity can be improved, par 
ticularly against a speci?c pathogen. 
[0015] A medical applicability of the compounds of the 
general formulae 1 to 3 as identi?ed according to the present 
invention Was yet unknoWn. A further aspect of the present 
invention thus relates to theiruse for a prevention or treatment 
of diseases, such as, for example, tumorous diseases or infec 
tious diseases. 
[0016] A further aspect of the present invention then relates 
to the use of a compound of the general formulae 1 to 3: 
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Wherein the residues Rl to R12 are as de?ned above, for an 
inhibition of the formation of bio?lms on surfaces. Prefer 
ably, the use relates to an inhibition of the formation of 
bio?lms through staphylococci, such as, for example, S. epi 
dermidis, on plastic and metal surfaces of medical implants, 
stents, catheters, cannulae, and other medical invasive 
devices. 
[0017] A further aspect of the invention relates to the use of 
the compounds according to the present invention as tools for 
studying and research of the formation of bio?lms, and as 
“Lead Structures” for the development of additional com 
pounds that inhibit the formation of bio?lms and are anti 
infective. 
[0018] In the context of the present invention, a “deriva 
tive” shall be a compound derived from the general formulae 
1 to 3, Which, for example, is substituted in several of the 
residues as given above for R1 to R12, as Well as mixtures of 
several of these compounds, Which, for example, can be con 
verted into a medicament that can be “personalized” for the 
disease to be treated and/or the patient, respectively, on the 
basis of diagnostic data or data With respect to the success of 
the therapy or progress thereof. 
[0019] A “precursor” of a substance in the context of the 
present invention shall mean, on the one hand, a substance 
Which during the course of its administration for a treatment 
is modi?ed by the conditions in the body (e.g. pH in the 
stomach, or the like) in such a Way, or after uptake is metabo 
liZed by the body in such a Way, that the compounds of the 
invention or their derivatives are formed as effective sub 
stances. 
[0020] The invention shall noW be further described in the 
folloWing With reference to the attached FIGURE, neverthe 
less, Without being limited thereto. 
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EXAMPLE 1 
Synthesis of the Isoquinolinium-Salt A (:Formula 
1 a) 
[0021] 
MeO \ Me 
(9 
/ O + 
MeO Me 
4 
HZN 
glacial acetic acid 
67% 
NH2 
5 
MeO \ Me 
(9 
/ N 
MeO Me Me 
Q 
N \ | 
Me 
MeO OM 
1a 
[0022] 200 mg (0.628 mmol) of the benZopyrylium-salt 4 
(produced according to G. Bringmann, Liebigs Ann. Chem. 
1985, 2126-2134) Were dissolved in 5 ml glacial acetic acid, 
57.9 mg (0.314 mmol) of benZidine (5) Were added, and Were 
stirred over night at room temperature. After reaction Was 
?nished, 5 ml of diethylether Were added to the suspension, 
and the precipitated solid Was removed by suction. The sol 
vent of the mother liquor Was removed in vacuo, and the oily 
residue Was puri?ed using column chromatography on 
SephadeX-LH20 (methanol+5% tri?uoro acetic acid). The 
isoquinolinium-salt A is obtained in the form of beige 
needles. 
N,N'-(1,1'-benZidine)-di-(6,8-dimethoxy-1,3 -dimeth 
ylisoquinolinium)-salt (A) 
[0023] Yield: 171 mg (0.210 mmol; 67%). 
[0024] Melting point: >350o C. (methanol) 
[0025] IR (KBr): ~LI3409 (br), 2949 (m), 2823 (W), 1687 
(m), 1643 (m), 1612 (s), 1559 (m), 1494 (W), 1466 (m), 1387 
(s), 1288 (W), 1201 (s), 1116 (s), 1027 (m), 970 (W), 837 (W), 
799 (W) cm_l. 
[0026] 1H-NMR (400 MHZ, DMSO): 6:2.29 (s, 6H, 
3-CH3), 2.91 (s, 6H, 1-CH3), 4.17 (s, 12H, OCH3), 7.09 (d, 
4.]:215 HZ, 2H, AriH), 7.21 (d, 4.]:215 HZ, 2H, AriH), 
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7.78 (d, 31:859 HZ, 4H, AriH), 8.15 (s, 2H, AriH), 8.28 
(d, 3.]:859 HZ, 4H, AriH) ppm. 
[0027] l3C-NMR (100 MHZ, DMSO): 6:21.63 (CH3), 
23.27 (CH3), 56.62 (OCH3), 57.12 (OCH3) 98.93, 102.2, 
110.19,121.68,127.45,129.10,139.41,140.21,141.78,144. 
05, 159.45, 161.36, 166.79 (AriC) ppm. 
[0028] MS (70 eV): m/Z (%) 586 (14) [M]", 369 (10), 353 
(8), 293 (24), 264 (8), 69 (13), 44 (49). 
[0029] C38H38N2O4 (HRMS): Calc. 586.2823; Found 586. 
2785. 
EXAMPLE 2 
Synthesis of the Dihydro Isoquinolinium-Salt 2a 
Production of the Secondary Amine (S)-8 
[003 0] 
MeO 5 \“Me 
NHZ + 
MeO 
6 
2(HO)B 
Cu(OAc)2, 2,6 
lutidine 
Myristic acid 
O2—atmosphere 
56% 
7 
MeO “\\Me 
H N 
MeO 
8 
[0031] 272 mg (2.55 mmol) of2,6-lutidine Were added to a 
suspension consisting of 658 mg (3.83 mmol) of 1-naphthyl 
boric acid (7), 0.926 mg (0.005 mmol) copper (II) acetate, and 
1.14 mg myristic acid in 5 ml absolutiZed toluene. After 5 
minutes, 500 mg (2.55 mmol) of primary amine 6 (produced 
according to G. Bringmann, R. Weirich, H. Reuscher, J. R. 
Jansen, L. KinZinger, T. Ortmann Liebigs Ann. Chem. 1993, 
877-888) Were added, and the reaction mix Was stirred for 30 
hours in an oxygen atmosphere at room temperature. Subse 
quently, the suspension Was diluted With 10 ml acetic ethyl 
ester, and ?ltered through silica (acetic ethyl ester). The sol 
vent Was removed in vacuo, and the product Was puri?ed 
using column chromatography (silica, petrolether:ethyl 
acetate:10:1). The secondary amine 8 Was obtained as a 
broWn oil. 
(2R)iN-(1-naphthyl)-1-(3',5'-dimethoXyphenyl)-2 
aminopropane (S)-8 
Yield: 459 mg (1.43 mmol; 56%). 
[0033] Rotation value: (XDI47O (c:0.10, dichloromethane) 
[0034] IR (KBr): ~LI3417 (br), 3098 (m), 2997 (m), 2918 
(W), 1595 (s), 1523 (W), 1459 (m), 1406 (W), 1385 (W), 1276 
(m), 1203 (m), 1149 (s), 1082 (W), 792 (W), 769 (s) cm_l. 
[0032] 
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[0035] lH-NMR (400 MHZ, MeOD): 6:1.32 (d, 31:644 
HZ, 3H, CH3), 2.85 (dd, 31:13.26 HZ, 2J:7.08 HZ, 1H, CH2), 
3.00 (dd, 31:13.27 HZ, 21:530 HZ, 1H, CH2), 3.69 (s, 6H, 
OCH3), 3.98 (m, 1H, CH), 6.31 (t, 1H, AriH), 6.43 (d, 
41:227 HZ, 2H, AriH), 6.74 (d, 31:758 HZ, 1H AriH), 
7.18 (d, 31:821 HZ, 1H, AriH), 7.34 (t, 1H, AriH), 7.42 
(m, 2H, AriH), 7.77 (dd, 31:947 HZ, 41:202 HZ, 1H, 
AriH), 7.96 (dd, 31:657 HZ, 4J:1.64 HZ, 1H, AriH) ppm. 
[0036] l3c-NMR (100 MHZ, MeOD): 67 :20.48 (CH3), 
43.10 (CH2), 50.87 (CH), 55.73 (OCH3), 99.50, 106.1, 108.7, 
117.8, 121.9,125.3, 125.4,126.7,127.8,129.5,136.3, 142.8, 
144.3, 162.4 (AriC) ppm. 
[0037] MS (70 eV): m/Z (%) 322 (2) [M+H]+, 221 (10) 
[M]", 234 (2), 170 (100), 154 (6), 128 (7), 115 (3), 91 (2), 77 
(3), 42 (2) 
[0038] C2IH24NO2 (HRMS): Calc. 322.18070; Found 322. 
18043. 
Production of the Amide (S)-9 
[0039] 
MeO S \\\\Me 
‘ ACCl, DMAP 
HN 78% 
MeO 
8 
9 
[0040] 138 mg (1.76 mmol) acetylchloride Were added 
drop-Wise at room temperature under a protective gas atmo 
sphere to a solution consisting of 256 mg (0.731 mmol) 
secondary amine 8 and 120 mg (0.877 mmol) DMAP in 15 ml 
toluene, and Were heated for 12 hours under re?ux. The 
cooled reaction mix Was spiked With Water, and extracted 
With acetic ethyl ester. The combined organic phases Were 
dried With MgSO4, and the solvent removed in vacuo. The 
residue Was chromatographed on silica With petrol ether: 
acetic ethyl ester (3:1). The amide 9 Was obtained in form of 
its tWo conformers (1 :0.7) in the form of beige platelets. 
(2R) -N,N-(1 -naphthyl-acetyl)-1 -(3', 5'-dimethox 
yphenyl)-2-aminopropane (S)-9 
Yield: 223 mg (0.615 mmol; 84%) 
Melting point: 1150 C. (petrol ether:acetic ethyl 
[0041] 
[0042] 
ester) 
[0043] Rotation value: 0tD:18o (c:0.10, methanol) 
[0044] IR (KBr): ~1I3428 (br), 2961 (s), 2838 (W), 1657 (s), 
1593 (s). 1507 (W), 1463 (s), 1428 (m), 1399 (m), 1380 (m), 
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1341 (W), 1320 (W), 1282 (s), 1240 (m), 1204 (m), 1159 (s), 
1054 (m), 1016 (m), 926 (W), 837 (m), 805 (m), 782 (s), 684 
(m), 601 (s) cm_l. 
[0045] 1H-NMR (400 MHZ, CDCl3): 6:0.78 (d, 3.1:694 
HZ, 3H, CH3), 0.95 (d, 3.1:694 HZ, 2H, CH3), 1.70 (s, 5H, 
CH3CO), 2.25 (dd, 31:13.01 HZ, 2.1:998 HZ, 0.7H, CH2), 
2.54 (dd, 31:12.63 HZ, 2.1:998 HZ, 1H, CH2), 3.19 (dd, 
31:13.01, 2.1:543 HZ, 0.7H, CH2), 3.31 (dd, 31:12.75 HZ, 
4.1:429 HZ, 1H, CH2), 3.72 (s, 4.2 HZ, OCH3), 3.81 (s, 6H, 
OCH3), 4.89 (m, 07H, CH), 5.09 (m, 1H, CH), 6.27 (d, 
4.1:202 HZ, 1.4H,AriH), 6.26 (t, 0.7H,AriH), 6.32 (t, 1H, 
AriH), 6.49 (d, 4.1:228, 1H, AriH), 7.13 (d, 3.1:619 HZ, 
0.7H, AriH), 7.29 (d, 4.1:101 HZ, 1H, AriH), 7.42-7.60 
(m, 5H, AriH), 7.81-7.99 (m, 5H, AriH) ppm. 
[0046] l3C-NMR (100 MHZ, CDCl3): 6:16.79 (CH3), 
19.24 (CH3), 23.18 (CH3), 23.33 (CH3), 41.78 (CH2), 43.54 
(CH2), 55.63 (OCH3), 55.70 (OCH3), 55.72 (CH), 57.55 
(CH). 99.56, 99.63, 108.2, 108.3, 124.11, 124.12, 126.71, 
126.74, 127.7, 127.8, 128.31, 128.37, 128.41, 128.5, 129.7, 
129.8,30.3,130.4,132.9,133.3,136.18,136.20,137.6,138. 
6, 142.56, 142.63 ppm. 
[0047] MS (70 eV): m/Z (%) 363 [M]+ (2), 185 (76), 170 
(100), 156 (32), 143 (38), 127 (23), 115 (15), 49 (17), 43 (38). 
[0048] C23H25NNaO3 (HRMS): Calc. 386.17266; Found 
386.17270. 
Production of the Dihydro lsoquinolinium-Salt (S)-2a 
[0049] 
MeO 5 \\\\Me 
“ Pocl3 
Oj/ N 98% 
MeO Me 
9 
MeO \‘\\\\Me TFAG) 
S 
Oj/ N M 
MeO Me 
22. 
36% de 
[0050] 0.01 ml POCl3 Were added to 7.00 mg ofamide 9 in 
2 ml absolute acetonitrile at room temperature, and heated for 
1 hour at re?ux. After cooling of the reaction mix to room 
temperature, Water+TFA (1%) Was added to the reaction mix, 
and the acetonitrile Was removed in vacuo. The remaining 
aqueous suspension Was extracted With acetic ethyl ester, the 
organic phases combined, dried With MgSO4, and the solvent 
removed. The residue Was puri?ed using gel chromatography 
(Sephadex, methanol), Whereby the isoquinolinium- salt (M) 
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2a and its atrop diastereomere (P)-2a (1 :0.4) Were obtained as 
yellow oil. Both diastereomeres could be separated using 
HPLC (Waters Symmetry C18, 45% Water+0.05% TEA, 55% 
methanol+0.05% TEA, isocratic, 0.7 ml/min: tR:8.1 min 
(M-2a), tR:8.7 min (P-2a)). 
(3S)iN,1'-naphthyl-6,8-dimethoxy-1,3-dimethyl-3, 
4-dihydroisoquinolinium-tri?uoro-acetate (M)-2a 
and (P)-2a 
Yield: 8.78 mg (0.019 mmol; 98%) 
[0052] Rotation value: otD:6° (c:0.25, methanol) 
[0053] IR (KBr): aw:3437 (br), 3020 (m), 2934 (m), 2843 
(W), 1650 (s), 1595 (s), 1508 (W), 1462 (m), 1428 (m), 1379 
(m), 1323 (m), 1288 (m), 1204 (m), 1152 (s), 1057 (m), 928 
(W), 833 (W), 807 (m), 780 (s), 686 (m) cm“. 
[0054] 1H-NMR (400 MHZ, MeOD): 6:1.29 (d, 31:682 
HZ, 1.3H, 3-CH3), 1.40 (d, 31:683 HZ, 3H, 3-CH3), 2.52 (s, 
1.3H, 1-CH3), 2.58 (s, 3H, 1-CH3), 3.21 (dd, 1:168 HZ, 
1:253 HZ, 1H, CH2), 3.27 (dd, 1:20.97 HZ, 1:467 HZ, 0.4H, 
CH2), 3.80 (dd, 1:158 HZ, 1:581 HZ, 0.4H, CH2), 3.96 (dd, 
1:168 HZ, 1:619 HZ, 1H, CH2), 3.98, 4.81 (s, 84H, OCH3), 
4.39 (m, 1H, CH), 4.66 (m, 04H, CH), 6.81 (m, 1.4H, 
AriH), 6.86 (m, 1.4H, AriH), 7.69-7.88 (m, 6H, AriH), 
7.98 (d, 1:833 HZ, 1H,AriH), 8.18 (m, 1.4H,AriH), 8.26 
(d, 1:808 HZ, 1.4 HZ, AriH) ppm. 
[0055] l3C-NMR (100 MHZ, MeOD): 6:16.79 (CH3), 
19.24 (CH3), 23.18 (CH3), 23.33 (CH3), 41.78 (CH2). 43.54 
(CH2), 55.63 (OCH3), 55.70 (OCH3), 55.72 (CH), 57.55 
(CH). 99.56, 99.63, 108.2, 108.3, 124.11, 124.12, 126.71, 
126.74, 127.7, 127.8, 128.31, 128.37, 128.41, 128.5, 129.7, 
129.8, 130.1,130.3, 130.5,130.7,132.3,132.5,134.0, 135.8, 
136.5, 136.20, 138.1, 142.56, 142.1, 142.70, 142.72, 166.6, 
170.8, 170.7, ppm. 
[0056] MS (70 eV): m/Z (%) 369 [M+Na]+ (2), 353 
(M+Na%H4), (3), 212 (22), 185 (52), 170 (100), 154 (7), 
143 (16), 127 (5), 43 (7). 
[0051] 
[0057] MS (ESl): 346.6 
EXAMPLE 3 
Synthesis of the Tetrahydro lsoquinoline 3a 
[0058] 
MeO \ Me 
@ NaBH4 
/ N 68% 
MeO Me 
lb 
MeO Me 
cis 
N 
MeO Me 
32. 
[0059] 57.2 mg (0.151 mmol) of NaBH4 Were added in 
portions at 0° C. to a solution of 56.0 mg (0.126 mmol) ofthe 
isoquinolinium-perchlorate 1b in 14 ml methanol. After stir 
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ring of the reaction mix at room temperature for 1 hour, 5 ml 
Water Were added, and the stirring continued for a further 12 
hours. The suspension Was then spiked With half-concen 
trated hydrochloric acid, and the product Was extracted With 
diethylether. The etheric phases Were pooled, dried With 
MgSO4, and the solvent removed in vacuo. The oily residue 
Was puri?ed on silica using column chromatography (hexane: 
ethyl acetate 1:2). The naphthyl tetrahydro isoquinoline 3a 
Was obtained as White solid. 
N-(1 -naphthyl)-6,8-dimethoxy- 1 ,3 -(cis) -dimethyl 
tetrahydro isoquinoline 3a 
Yield: 30.0 mg (0.103 mmol; 68%). 
[0061] Melting point: 690 C. (hexane:ethyl acetate) 
[0062] IR (KBr): ~I3432 (br), 3043 (s), 2990 (s), 2926 (s), 
2835 (m), 1687 (m), 1608 (s), 1490 (W), 1459 (m), 1423 (W), 
1391 (W), 1364 (W) 1341 (W), 1321 (W), 1295 (W), 1260 (m), 
1234 (W), 1207 (m), 1150 (s), 1109 (s), 1094 (s), 1049 (s), 
1023 (s), 941 (W), 826 (W), 802 (m), 779 (s) cm_l. 
[0063] 1H-NMR (400 MHZ, CDCl3): 6:0.87 (d, 31:631 
HZ, 3H, 3-CH3), 2.91 (d, 31:632 HZ, 3H, 1-CH3), 2.77 (dd, 
31:15.29 HZ, 21:290 HZ, 1H, CH2), 2.89 (dd, 31:15.03 HZ, 
21:935 HZ, 1H, CH2), 3.42 (m, 1H, 3-CH), 3.78 (s, 3H, 
OCH3), 3.86 (s, 3H, OCH3), 4.57 (q, 1H, 1-CH), 6.32 (d, 
41:228 HZ, 1H, AriH), 6.58 (d, 41:228 HZ, 1H, AriH), 
7.40-7.48 (m, 5H,AriH), 7.68 (d, 3J:7.71 HZ, 1H,AriH), 
7.82 (dd, 31:606 HZ, 4J:3.41 HZ. 1H, AriH) ppm. 
[0064] l3C-NMR (100 MHZ, CDCl3): 6:24.11 (CH3), 
28.37 (CH3), 39.88 (CH2), 55.45 (CH), 55.89 (OCH3), 56.07 
(OCH3), 97.34, 104.7, 109.2, 122.8, 124.8, 125.3, 125.6, 
126.0, 126.3,126.5,126.9, 128.5, 128.7,138.5,157.9, 159.4 
(Ar%). 
[0065] MS (70 eV): m/Z (%) 347 (5) [M]", 332 (100) 
[M—CH3], 316 (7) [M—OCH3]+, 189 (8) [M-naphthyl]+, 127 
(17) [naphthyl]+, 40 (12). 
[0060] 
C23H25NO2(347.4501) Calc. c 79.51 H 7.25 N 4.03 
Found c 79.29 H 7.59 N 3.87 
EXAMPLE 4 
Biological activities 
1. Effect Against Parasites of the Genus Leishmania 
[0066] Leishmania major-promastigotes (MHOM/IL81/ 
FE/BNI) Were cultivated in blood agar-cultures at 26° C., 5% 
CO2, and 95% humidity. For the experiment, the promastig 
otes Were Washed tWice With saline phosphate buffer (PBS) 
and subsequently suspended (108 cells/ml) in Click-RPMI 
1640-medium Without phenol red, spiked With 10% FCS, 2 
mM L-glutamine, 1.0 mM HEPES-buffer, pH 7.2, 100 ug/ml 
penicillin, 160 mg/ml gentamycin, 7.5% NaHCO3 and 50 [1M 
2-mercaptoethanol (culture medium). For the determination 
of activity, 200 pl of the promastigote-suspension in microti 
ter plates Were each incubated With the compounds in a geo 
metric series of dilutions for 24 hours at 26° C., 5% CO2, and 
95% humidity. Subsequently, 20 ul Alamar Blue (Trinova 
Biochem, Gie[3en, Germany) Were added to each of the 
microcultures, and the cultures Were incubated further. Cul 
tures that only contained medium and the compound, or only 
cellular suspension (Without compound), served as controls. 
The optical density Was measured after another 24 hours With 
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an ELISA-reader at the Wave lengths 550 nm and 630 nm. The 
lCso-values of the compounds Were calculated through linear 
interpolation (J. Mikes, D. Steverding. Parasitol. Int. 2000, 
48, 265-269). 
[0067] Macrophages of the cell line 1774.1 Were Washed 
and suspended in culture medium (2><108 cells/ml. For the 
test, 200 [1.1 of the cell suspension and the compounds Were 
pipetted in a geometric series of dilutions into cultures on 
microtiter plates. Following 24 hours of incubation at 37° C., 
5% CO2, and 95% humidity, 20 ul Alamar Blue Were added to 
each micro-culture, and the microtiter plate Was incubated 
further. Micro-cultures With medium and the compound as 
Well as micro-cultures that only contained cellular suspension 
(Without compound), served as controls. The optical density 
Was measured after 24, 48, and 72 hours With an ELISA 
reader at the Wavelengths 550 nm and 630 nm. The ICSO 
values of the compounds Were calculated using linear inter 
polation. Amphotericin B served as a reference compound 
and positive control. 
[0068] The activities of the compounds of the general struc 
tures 1-3 against leishmania Were examined in a series of 
examples according to the method as described above. The 
therapeutic index is the ratio of cytoxicity against host cells 
(1774.1 macrophages) to the activity against Leishmania 
major. 
TABLE 1 
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[0069] The compounds as exemplary shoWn in Table 1 
shoW an excellent effect against L. major. Here, in particular 
the compounds With alkyl substituents in the aryl residue 
shoW a very good and particularly selective effect against this 
pathogen. Thereby, compound D served as preferred lead 
compound, Which is also suited for a further chemical deriva 
tiZation. 
2. Anti-Trypanosome Effects 
[0070] Bloodstream-forms of the strain TC-221 of Trypa 
nosoma brucei brucei Were cultivated in enriched BaltZ-cul 
ture medium in an atmosphere von 5% CO2 at 37° C. For 
activity determinations, a de?ned number of pathogens (104 
trypanosomes per ml) Were incubated in 96-Well-plates With 
the compounds in different concentrations for 48 to 72 hours. 
The effect of the drugs Was quanti?able using the ED50 
values With linear interpolation. The trypanocidal activity of 
the test compounds Was determined through measuring 
absorption on an MR 700 microplate reader (test Wavelength 
550 nm, reference Wavelength 630 nm) by means of Alamar 
Blue®, an indicator of metabolic cellular functions. The addi 
tion of the dye took place 24 hours after starting the incuba 
tion. The color change of Alamar Blue® as used in this 
absorption measurements is based on reduction processes 
Exemplary effect against Leishmania major as Well as their therapeutic index. 
Examples for test compounds IC5O ([JM) Therapeutic index 
B MeO Me 2.45 
6 \ BF4 
@ 
/ N 
MeO Me 
Me 
0 e 2.02 
TFA 
MeO Me 
\ Me 
(*3 
/ N 
MeO Me 
eM 
D 9 0.85 
TFA 
MeO Me \ 
G) 
/ N 
MeO Me 
Amphotericin B 2.51 
13 
17 
18 
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involving NADH or NADH-dependent enzymes. Incubation 
times and the concentrations of dye as required correlate With 
the metabolic activities of the trypanosomes. The MIC-value 
(minimum inhibitory concentration) Was determined micro 
scopically through counting of living cells in Neubauer 
counting chambers. Suramine Na served both as positive 
control and reference. 
[0071] The anti-trypanosomal activities of the compounds 
of the general structures 1-3 Were studied based on a series of 
examples according to the above-described methods. The 
therapeutic index is the ratio of the cytoxicity (1774.1 mac 
rophages) to the activities against Trypanosoma brucei bru 
cez. 
TABLE 2 
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3. Anti-Plasmodium Effects 
[0073] For the determination of the anti-plasmodium 
activities, cultures of Plasmodiumfalciparum strain K1 (re 
sistant against chloroquine and pyrimethamine) Were used. A 
modi?cation (R. G. Ridley, W. HofheinZ, if Matile, C. Jac 
quet, A. Dom, R. Masciadri, S. Jolidon, W. F. Richter, A. 
GuenZi, M. A. Girometta, H. UrWyler, W. Huber, S. Thaitong, 
W. Peters, Antimicrob. Agents Chemother 1996, 40, 1846 
1854) of the [3 H] -hypoxanthine-inclusion-test (R. E. Desjar 
dins, C. J. Can?eld, D. Haynes, J. Chulay, Antimicrob. Agents 
Chemother 1979, 16, 710-718) Was used. Human red blood 
cells infected With P falciparum (0.3% infection) at a hema 
Exemplary effects against Trypanosoma brucei brucei after 48 and 72 hours as Well 
as their therapeutic index. 
EDso (PM) EDso (PM) 
Examples for test compounds after 48 h after 72 h Therapeutic index 
E MeO Me 0.383 0.323 86 
9 
B134 
/ N 
MeO Me 
0 
Me 
ld 
F MeO Me 0.325 0.311 72 
\ G) 
TFA 
/ N 
MeO Me 
O OMe 
Me 
2a M60 “M6 9 0.390 0.356 >180 
A“ TFA 
S 
G 
/ N M 
># 
MeO Me 
SUI3IH1H Na 0.31 0.32 nd 
[0072] The compounds as exemplary shoWn in Table 2 have 
a pronounced effect against T brucei brucei. Especially those 
compounds With electron-pushing substituents in N-aryl 
substituents in the in-vitro-model exhibited a selective effect 
against this pathogen, at good therapeutic indices. In tests of 
these compounds against other cells, such as L5178Y mice 
lymphoma-cells, also relatively loW cytotoxicities (ED5O>10 
uM) could be found When the cells Were held under groWth 
conditions, in Which the generation time of 12 hours is 
increased to 18 hours. Thereby, compound 2a served as pre 
ferred lead compound, Which is also suitable for a further 
chemical derivatiZation. 
tocrit of 2.5% (volume fraction of the red blood cells) in 
RPMI 1640 medium With the serum replacement Albumax H 
(5 g/L) Were incubated With serial dilutions of the drugs in 
microtiter plates for 48 hours at 370 C. under a CO2-enriched 
and OZ-reduced atmosphere. Then, 0.5 uCi [3H]-hypoxan 
thine Were added to each Well of the microtiter plate, and after 
a further 24 hours of incubation time the Wells Were harvested 
With a Betaplate Cell Harvester onto glass ?ber ?lters, and 
lysed With distilled Water. The incorporation of radio-labeled 
hypoxanthine (Which correlates With the quantity of living 
parasites) Was determined using a scintillation counter. The 
1C5O value Was determined from sigmoidal inhibition curves. 
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The tests Were performed in duplicate, and repeated at least 
once. Parasite cultures Without additive served as control 
(100% incorporation), cultures With a dilution series of chlo 
roquine served as positive control. 
[0074] The anti-plasmodia activities of the compounds of 
the general structures 1-3 Were studied based on a series of 
examples according to the above-described methods. The 
therapeutic index is the ratio of the IC5O values for rat myo 
blasts (L-6-cells:cytotoxicity) to the IC5O values for Plasma 
diumfalciparum. 
TABLE 3 
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ug/ ml) Which under experimental conditions still barely 
inhibits the growth of the pathogen. In this method, a series of 
dilutions With decreasing concentrations of drug is produced 
in 96-Well-microtiter plates from a stock solution of the com 
pound. The drug-containing microtiter plate-Wells are inocu 
lated With a de?ned amount of the pathogen to be tested, and 
cultivated. The concentration of the compound in the Well, 
Where no more turbidity of the medium due to a groWth of the 
pathogens could be optically detected is given as the MIC. 
Exemplary effects against Plasmadiamfalczparum as Well as their therapeutic 
index. 
Examples for test compounds IC5O (11M) Therapeutic index 
G MeO Me 0.056 671 
\ 6 
C104 
/ N 
MeO Me 
Cl 
H MeO Me 0.282 324 
\ G) 
@ TFA 
/ N 
MeO Me 
0113 
1 MeO Me 0.211 >841 
\ 6 
@ TFA 
N / O 
MeO Me i 
N Me 
H 
chloroquine 0.119 nd 
[0075] It can be seen that in particular compounds With the Technique 
para-positioned acyl amido group, such as, for example, I _ _ _ _ _ 
exhibit a pronounced activity against strain K1 of R falci- [0078] The test Strams Were Inoculated 1n Luna'Benam' 
parum, Without a detectable cytotoxicity. Thereby, compound 
I served as the preferred lead compound, Which is also suit 
able for a further chemical derivatiZation. 
4. Growth-Inhibiting Effect (Exemplary forA (See Example 
1) on Gram-Positive Bacteria of the Genus Staphylococcus 
and Yeasts of the Species Candida albicans 
[0076] Use: a) Therapy and prevention of infections 
through Gram-positive bacteria and pathogenic yeasts in 
human and veterinary medicine; b) Conservation of foods, 
medicines and cosmetics through loWering the germ load 
and/ or prevention of the colonialiZation through Gram-posi 
tive bacteria and yeasts. 
Examination of the Inhibitory Effect Through Determining of 
the Minimal Inhibitory Concentration (MIC) in the Micro 
Bouillon-Dilution Methods 
[0077] The MIC (minimal inhibitory concentration) is the 
loWest concentration of an antibiotic compound (in 11M or 
medium, and groWn over night in a shaking incubator at 37° 
C. until stationary groWth phase. On the folloWing day, the 
culture Was diluted 1:100 With fresh Miiller-Hinton-bouillon 
(MH-Medium) containing 5% NaCl (W/v), and until logarith 
mic groWth phase incubated again at 37° C. inkubiert. The 
optical density of the bacterial suspension Was photometri 
cally measured at 550 nm, and the suspension adjusted at 
2><105 colony forming units/ml (CFU/ml). In the meantime, a 
geometric series of dilutions of the test compounds Was pro 
duced in MH-medium. 100 pl of each dilution Were pipetted 
into the corresponding Wells of a 96-Well-polystyrene-?at 
bottom-microtiter plate. The plates Were inoculated With 100 
pl of the pre-prepared inoculum, and cultured in the incubator 
for 18 hours at 37° C. On the folloWing day, the optical density 
of the bacterial cultures in the Wells Was determined With an 
ELISA-reader at a Wavelength of 550 nm, compared to the 
blank value (:non-inoculated MH-medium). The concentra 
tions of the compound in the last Wells, Wherein no more 
groWth of the pathogens could be detected, is given as the 
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MIC. A loW MIC indicates a high inhibitory activity of a 
compound, Whereas a high concentration indicates a loW 
activity. 
Results 
[0079] The MIC of, for example, A Was tested for the fol 
lowing germs and strains: 
[0080] Staphylococcus aureus 325: Bio?lm-positive clini 
cal isolate from blood culture, Wild type 
[0081] Staphylococcus aureus NCTC 8325: Bio?lm-nega 
tive reference strain, genome published 
[0082] Staphylococcus epidermidis RP62A: Bio?lm-posi 
tive, multi resistant reference strain 
[0083] Escherichia coli 536: urinary tract isolate, reference 
strain 
[0084] Pseudomonas aeruginosa: environmental isolate 
[0085] Candida albicans 5314: clinical isolate 
TABLE 4 
Minimal inhibitory concentrations of A against several infectious 
pathogens 
Minimal inhibitory 
concentrations 
Strain ([JM) 
Staphylococcus aureus 325 0.63 
Staphylococcus aureus NCTC 5.00 
8325 
Staphylococcus epidermidis 0.63 
RP62A 
Escherichia coli 536 20.00 
Pseudomonas aeruginosa >160 
Candida albicans 5314 1.25 
Determination of the Cytotoxicity by the Alamar-Blue®-As 
say With the Example of Substance A 
[0086] The cytotoxicity of A Was determined by means of 
anAlamar-Blue®-assay. First, a geometric series of dilutions 
of A in cellular medium (293 kidney epithelial cells; Without 
phenol red) With 1% DMSO Was produced, and in a 96-well 
polystyrol-?at bottom-microtiter plate vorgelegt. The cells 
Were trypsiniZed, and Washed once. For the test, a cellular 
suspension of 105 cells/ml Was prepared, and 20 [11 thereof 
Were pipetted into the Wells. The ?nal volume Was 200 [1.1. 
After 24 h incubation at 370 C. and 5% CO2, 20 ul Alamar 
Blue (Trinova Biochem, Gie[3en, Germany) Was added into 
each Well, and the microtiter plate Was incubated further. The 
Wells that contained the medium and substance, as Well as 
those that only contained cellular suspension (Without sub 
stance), served as negative or positive control, respectively. 
The optical density Was measured after 24 h and 48 h With an 
ELISA-reader at the Wavelengths 550 nm and 630 nm. The 
IC5O value forA Was calculated folloWing linear interpolation 
(W. Huber, J. C. Koella Acta Tropica 1993, 55, 257-261). 
TABLE 5 
Cytotoxicity of A and its therapeutic index against both bio?lm 
fonning staphylococcus-strains, as Well as against C. albicans 
293 Kidney Staphylococcus Candida 
epithelial Staphylococcus epidermidis albicans 
cells aureus 325 RP62A 5314 
42.44 M 67 67 34 
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[0087] As can be seen from Table 2, A has an outstanding 
groWth-inhibiting effect against Gram-positive infectious 
pathogens, such as staphylococci, as Well as against yeasts of 
the species candida albicans, Wherein this effect is particu 
larly pronounced against both bio?lm-forming staphylococ 
cus-strains. In addition, these strains also exhibit a good 
therapeutic index. The substance has a loWer effect against 
enterobacteria, such as E. coli, and is fully ineffective against 
pseudomonades. 
5. Inhibition of the Formation of Bio?lms by Pathogenic 
Staphylococci (Exemplary forA and S. epidermidis RP62A) 
[0088] Use: a) Therapy and prevention of foreign matter 
associated infections through bio?lm-forming staphylococci 
in the human and veterinary medicine; b) Prevention of the 
generation of a staphylococci-bio?lm on plastic and metal 
surfaces 
Determination of the Formation of Bio?lms of Staphylococci 
on Polystyrene-Surfaces (Bio?lm Test) 
Technique 
[0089] For determining the effect of a test compound on the 
formation of bio?lms of staphylococci, the bio?lm-reference 
strain S. epidermidis RP62A is inoculated in trypticase-soy 
broth (TSB) With a common 0.25% (W/v) glucose concentra 
tion (standard-TSB), and groWn over night at 370 C. in a 
shaking incubator until the stationary groWth phase. On the 
next day, the cultures are diluted 1:100 With fresh TSB, and 
100 pl of this germ suspension are pipetted into the Wells of a 
96-Well-polystyrol-tissue culture plate With ?at bottom 
(Greiner, Niirtingen, Germany). In the meantime, also a geo 
metric series of dilutions of the test substance is produced in 
TSB, and also 100 [1.1 of each of these dilutions are added to 
the den germ suspensions. The plates Were incubated at 370 C. 
in an incubator for 18 hours at 370 C. On the next day, ?rst the 
groWth of the cultures is checked through determining of the 
optical density at 550 nm by means of an ELISA-reader (see 
also at MIC-determination), and documented. Then, the cul 
tures are carefully poured out of the Wells, and the plates Were 
Washed three times With phosphate-buffered saline solution 
(PBS), in order to remove non-adherent bacteria. The plates 
are then dried on a heating block at about 60° C., Whereby 
adherent bacteria are heat-?xed. For dying of the bio?lm, then 
100 [1.1 of a saturated aqueous crystal violet-solution are pipet 
ted into each of the Wells of the plates, that Were removed after 
5 minutes. Excess dye is subsequently rinsed off under excess 
running Water. After drying, the density of the adherent bio 
?lm is determined With an ELISA-reader at a Wavelength of 
490 nm. 
Results 
[0090] As can be seen from FIG. 1,A outstandingly inhibits 
the formation of bio?lms of the reference strain S. epidermi 
dis RP62A. At a drug concentration of 0.63 uM, Which 
exactly corresponds to the MIC of the substance in this strain, 
an about 90% reduction of the formation of bio ?lms com 
pared to a control Without the substance can be detected (FIG. 
1). This effect decreases in a dose-dependent manner. Inter 
estingly, the bio?lm-inhibiting effect is still markedly detect 
able at those concentrations, Which are obviously already too 
loW to in?uence the groWth of the bacteria. Thus, in addition 
to the above-described groWth-inhibiting effect, the sub 
stance exhibits an anti-bio?lm effect on staphylococci that is 
independent thereof. 
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[0091] FIG. 1 shows the effect of different concentrations 
ofA on the growth and formation of bio?lms of S. epidermidis 
RP62A. 
1-13. (canceled) 
14. An anti-infective as Well as bio?lm-inhibiting com 
pound of the general formula 3 
R12 R10 
Wherein each of R1 to R6 and R8 to R12 is independently, 
either H; a non-sub stituted, mono substituted or polysub 
stituted C 1 -Cl S-alkyl; alkenyl; a non-substituted, mono 
substituted or polysub stituted aryl or heteroaryl residue; 
a non-substituted, monosubstituted or polysubstituted 
benZyl group; an acyl group; an alkoxy substituent; an 
alkyl group bound through a sulfur atom; or a nitrogen 
substituent; 
R7 independently can be either H; a non-substituted, mono 
substituted or polysubstituted C l-C ls-Alkyl, Wherein 
the alkyl can be straight, branched or cyclic; a monosub 
stituted or polysubstituted, straight, branched or cyclic 
C l-C ls-alkenyl; or an acyl group; 
and R8 to R12 can be bonded in a manner that thereby a 
non-substituted, monosubstituted or polysubstituted 
ring and dimers of 3 is generated, or a pharmaceutically 
acceptable salt or solVate of this compound. 
15. A composition formulated for the treatment and/or 
prevention of diseases and/or the inhibition of bio?lms 
Wherein said composition comprises an anti-infective as Well 
as bio?lm-inhibiting compound of the general formulae 1 to 
3 
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-continued 
2 
R4 R3 
R5 R2 
R8 
@ 9 
R6 / N R 
R70 R1 
R12 R10 
R11 
3 
R4 R3 
R5 R2 
R8 
N R9 
R6 
R70 R1 
R12 R10 
R11 
Wherein each of R1 to R6 and R8 to R12 is independently, 
either H; a non- sub stituted, monosubstituted or polysub 
stituted C l-C ls-alkyl; Wherein the alkyl can be straight, 
branched or cyclic; alkenyl; a non-substituted, mono 
substituted or polysub stituted aryl or heteroaryl residue; 
a non-substituted, monosubstituted or polysubstituted 
benZyl group; an acyl group; an alkoxy substituent; an 
alkyl group bound through a sulfur atom; a sulfonyl 
group; or a nitrogen substituent; 
R7 independently can be either H; a non-substituted, mono 
substituted or polysubstituted Cl-Cls-Alkyl, Wherein 
the alkyl can be straight, branched or cyclic; a monosub 
stituted or polysubstituted, straight, branched or cyclic 
C l-C ls-alkenyl; or an acyl group; 
and R8 to R12 can be bonded in a manner that thereby a 
non-substituted, monosubstituted or polysubstituted 
ring and dimers of l is generated, or a pharmaceutically 
acceptable salt or solVate of this compound, With the 
provisio that formulae l-3 do not mean the folloWing 
formulae 
MeO Me 
MeO Me 
OMe 
Me OMe 
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-continued 
MeO \\‘ 
® 
/ N 
MeO Me 
OMe 
Me OMe 
MeO “\Me 
S\“ OH OMe 
(D 
/ N 
MeO Me 
Me 
MeO Me \ 
@ 
/ N 
MeO Me © 
MeO Me \ 
G) 
/ N 
MeO Me 
and wherein the composition is formulated for the treat 
ment and/ or the prevention of diseases and the inhibition 
of bio?lms. 
16. The compound according to claim 14 of the formulaA 
la 
MeO \ Me 
/N 
MeO Me 
Me 
I‘EI \ 
Me 
MeO OMe 
or a pharmaceutically acceptable salt or solvate of this 
compound. 
12 
Nov. 11, 2010 
17. The compound according to claim 14 of the formula 
TFAe 
\ Me 
(9 
/N 
MeO 
MeO Me 
or a biologically active derivative, pharmaceutically 
acceptable salt, or solvate of this compound. 
18. The compound according to claim 14 of the formula 
S 
MeO 
MeO Me 
or a biologically active derivative, pharmaceutically 
acceptable salt, or solvate of this compound. 
19. The compound according to claim 14 of the formula 
MeO Me \ TFAe 
N63 / O 
MeO Me i 
N 
H 
Me 
or a biologically active derivative, pharmaceutically 
acceptable salt, or solvate of this compound. 
20. A method for producing a compound according to 
claim 18, comprising the reaction of 2,6-lutidine, l-naphthyl 
boric acid, copper (ll) acetate, and myristic acid With a pri 
mary amine. 
21. A pharmaceutical composition comprising a therapeu 
tically effective amount of a compound according to claim 14, 
optionally together With suitable additives or excipients. 
22. The pharmaceutical composition according to claim 
21, characterized in that the compound is present in the form 
of a depot substance, or as a precursor, together With a suitable 
pharmaceutically acceptable diluent or carrier substance. 
23. The pharmaceutical composition according to claim 
21, characterized in that it is present as surface coating, as 
additive of materials or solutions for rinsing. 
24. The pharmaceutical composition according to claim 21 
in the faint of a tablet; dragée; capsule; drop-solution; sup 
pository; preparation for injection or infusion; or for peroral, 
rectal or parenteral use. 
25. A method for the prevention of the formation of bio 
?lms on surfaces, and/or for the treatment and/ or prophylaxis 
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of infection diseases, wherein said method comprises the use 
of a compound of the general formulae 1 to 3 
R4 R3 
R5 R2 
\ R8 
6 9 
R6 / N R 
R70 R1 
R12 R10 
R11 
2 
R4 R3 
R5 R2 
R8 
(*3 9 
R6 / N R 
R70 R1 
R12 R10 
R11 
3 
R4 R3 
R5 R2 
R8 
N R9 
R6 
R70 R1 
R12 R10 
R11 
Wherein each of R1 to R6 and R8 to R12 is independently, 
either H; a non-sub stituted, mono substituted or polysub 
stituted C l-C ls-alkyl; Wherein the alkyl can be straight, 
branched or cyclic; alkenyl; a non-substituted, mono 
substituted or polysub stituted aryl or heteroaryl residue; 
a non-substituted, monosubstituted or polysubstituted 
benZyl group; an acyl group; an alkoxy substituent; an 
alkyl group bound through a sulfur atom; a sulfonyl 
group; or a nitrogen substituent; 
R7 independently can be either H; a non-substituted, mono 
substituted or polysubstituted Cl-Cls-Alkyl, Wherein 
the alkyl can be straight, branched or cyclic; a monosub 
stituted or polysubstituted, straight, branched or cyclic 
Cl-Cls-alkenyl; or an acyl group; and R8 to R12 can be 
bonded in a manner that thereby a non-substituted, 
monosubstituted or polysubstituted ring and dimers of l 
is generated, or a pharmaceutically acceptable salt or 
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solvate of this compound, With the provisio that formu 
lae 1-3 do not mean the folloWing formulae 
MeO Me 
OMe 
MeO 
OMe 
MeO Me 
‘ OH OMe S 
@ 
/ N 
MeO Me 
Me 
MeO Me 
MeO Me 
26. The method according to claim 25 for a treatment 
and/or the prophylaxis of malaria, or the prevention of the 
formation of bio?lms by S. epidermidis. 
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27. The composition, according to claim 15, comprising a 
compound of the formula A (:la): 
MeO \ Me 
MeO M6 %\ Me 
\ 
Me 
la 
MeO OMe 
and/or a pharrnaceutically acceptable salt or solvate of this 
compound. 
28. The composition, according to claim 15, comprising a 
compound of the formula: 
MeO Me 
MeO Me 
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and/or a biologically active derivative, pharrnaceutically 
acceptable salt, or solvate of this compound. 
29. The composition, according to claim 15, comprising a 
compound of the formula: 
MeO MMe TFAQ 
S 
MeO Me 
and/or a biologically active derivative, pharrnaceutically 
acceptable salt, or solvate of this compound. 
30. The composition, according to claim 15, comprising a 
compound of the formula: 
MeO Me \ TFAe 
N63 / O 
MeO Me i 
N 
H 
Me. 
and/or a biologically active derivative, pharrnaceutically 
acceptable salt, or solvate of this compound. 
* * * * * 
